Αρχική World News Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive... World News Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC Από Ogkologos - 14 Ιουλίου, 2026 255 0 Facebook Twitter Google+ Pinterest WhatsApp Findings after 7 years of follow-up in the CROWN study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Helping Kids with Cancer Speak for the Supportive Care They Need 13 Δεκεμβρίου, 2024 EMA Recommends Granting a Marketing Authorisation for Capmatinib 13 Μαΐου, 2022 Predicting future breast cancer with precision 22 Μαρτίου, 2021 Women in Science: Celebrating with our Women of Influence initiative 15 Μαρτίου, 2023 Φόρτωση περισσοτέρων HOT NEWS To Treat Pancreatic Cancer, Mouse Study Suggests Altering Tumor Microbiome FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer Looking back at a life-changing clinical trial Neoadjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy Can Be Delivered Safely in Patients with Operable...